Next-generation therapies for pancreatic cancer

References

• Society AC. Cancer facts and figures 2023. American Cancer Society. 2023.
   Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi: 10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Owens DK, Davidson KW, Krist AH, et al. Screening for pancreatic cancer. JAMA. 2019;322(5):438. doi: 10.1001/jama.2019.10232
   PubMed Web of Science ®Google Scholar
• Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International pancreatic cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23(7):1880–1888. doi: 10.1093/annonc/mdr541
   PubMed Web of Science ®Google Scholar
• Salem ME, El-Refai SM, Sha W, et al. Landscape of KRAS G12C , associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS -mutated cancers. JCO Precision Oncol. 2022;(6):6. doi: 10.1200/PO.21.00245
   Google Scholar
• Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009 Apr 15;69(8):3681–3688. doi: 10.1158/0008-5472.CAN-09-0015
   PubMed Web of Science ®Google Scholar
• Wang Y-T, Gou Y-W, Jin W-W, et al. Association between alcohol intake and the risk of pancreatic cancer: a dose–response meta-analysis of cohort studies. BMC Cancer. 2016;16(1). doi: 10.1186/s12885-016-2241-1
   Google Scholar
• Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):765–776.
   PubMed Web of Science ®Google Scholar
• Sung H, Siegel RL, Rosenberg PS, et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health. 2019;4(3):e137–e147. doi: 10.1016/S2468-2667(18)30267-6
   PubMed Web of Science ®Google Scholar
• Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the metabolic syndrome and cancer project. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2307–2317. doi: 10.1158/1055-9965.EPI-10-0234
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10–27. doi: 10.14740/wjon1166
   PubMedGoogle Scholar
• Ben-Aharon I, van Laarhoven HWM, Fontana E, et al. Early-onset cancer in the gastrointestinal tract is on the rise—evidence and implications. Cancer Discovery. 2023;13(3):538–551. doi: 10.1158/2159-8290.CD-22-1038
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures 2023. American Cancer Society. 2023;23.
   Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. Ca A Cancer J Clinicians. 2021;71(1):7–33. doi: 10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):3217–3230. doi: 10.1200/JCO.20.01364
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma (Version 2. 2023). 2023 June 19, [cited 2023 Oct 2]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
   Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi: 10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Macarulla T, Pazo-Cid R, Guillén-Ponce C, et al. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol. 2019;37(3):230–238. doi: 10.1200/JCO.18.00089
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272–1281. doi: 10.1016/S0140-6736(23)01366-1
   PubMed Web of Science ®Google Scholar
• Hu ZI, O’Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023 Oct 5;21: 7–24.
   PubMed Web of Science ®Google Scholar
• Ohba A, Ozaka M, Ogawa G, et al. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial. Ann Oncol. 2023;34:S894. doi: 10.1016/j.annonc.2023.09.2565
   Web of Science ®Google Scholar
• Carrato A, Pazo-Cid R, Macarulla T, et al. Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: the SEQUENCE trial. J Clin Oncol. 2022;40(16_suppl):4022. doi: 10.1200/JCO.2022.40.16_suppl.4022
   Web of Science ®Google Scholar
• Carrato A, Vieitez JM, Benavides M, et al. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: phase I results. Eur J Cancer. 2020 Nov 1;139:51–58.
   PubMed Web of Science ®Google Scholar
• Westphalen B, Gaska T, Reichert M, et al. FOOTPATH: a randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC). J Clin Oncol. 2023;41(16_suppl):4021. doi: 10.1200/JCO.2023.41.16_suppl.4021
   Web of Science ®Google Scholar
• Dahan L, Williet N, Le Malicot K, et al. Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial. J Clin Oncol. 2021;39(29):3242–3250. doi: 10.1200/JCO.20.03329
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317–327. doi: 10.1056/NEJMoa1903387
   PubMed Web of Science ®Google Scholar
• Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-Mutated metastatic pancreatic cancer. J Clin Oncol. 2022 Dec 1;40(34):3929–3939. doi: 10.1200/JCO.21.01604
   PubMed Web of Science ®Google Scholar
• Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol. 2022 Aug;23(8):1009–1020. doi: 10.1016/S1470-2045(22)00369-2
   PubMed Web of Science ®Google Scholar
• Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142(4):730–733.e9. doi: 10.1053/j.gastro.2011.12.042
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch A-M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. doi: 10.1038/nature14169
   PubMed Web of Science ®Google Scholar
• SD AC, Forrester K, Martin J, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988 May 20;53(4):549–554. doi: 10.1016/0092-8674(88)90571-5
   PubMed Web of Science ®Google Scholar
• Jones SN, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806. doi: 10.1126/science.1164368
   PubMed Web of Science ®Google Scholar
• Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr;17(4):500–503.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016 Mar 01;531(7592):47–52. doi: 10.1038/nature16965
   PubMed Web of Science ®Google Scholar
• Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genet. 2015;47(10):1168–1178. doi: 10.1038/ng.3398
   PubMed Web of Science ®Google Scholar
• Rashid NU, Peng XL, Jin C, et al. Purity Independent subtyping of tumors (PurIST), a clinically robust, single-sample Classifier for tumor subtyping in pancreatic cancer. Clin Cancer Res. 2020 Jan 1;26(1):82–92. doi: 10.1158/1078-0432.CCR-19-1467
   PubMed Web of Science ®Google Scholar
• Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–1354. doi: 10.1158/1078-0432.CCR-17-2994
   PubMed Web of Science ®Google Scholar
• O’Kane GM, Grünwald BT, Jang GH, et al. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020 Sep 15;26(18):4901–4910. doi: 10.1158/1078-0432.CCR-19-3724
   PubMed Web of Science ®Google Scholar
• Knox JJ, Jaffee EM, O’Kane GM, et al. PASS-01: Pancreatic adenocarcinoma signature stratification for treatment–01. J Clin Oncol. 2022;40(4_suppl):TPS635. doi: 10.1200/JCO.2022.40.4_suppl.TPS635
   Web of Science ®Google Scholar
• Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med. 2002 Dec;8(12):571–576. doi: 10.1016/S1471-4914(02)02434-6
   PubMed Web of Science ®Google Scholar
• DC VG, Hoeijmakers JHJ, Kanaar R. Chromosomal stability and the DNA double-stranded break connection.Nat Rev Genet. 2001 Mar 1;2(3):196–206. doi: 10.1038/35056049
   PubMed Web of Science ®Google Scholar
• Walsh CS. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015 May;137(2):343–350. doi: 10.1016/j.ygyno.2015.02.017
   PubMed Web of Science ®Google Scholar
• Shin DS, Chahwan C, Huffman JL, et al. Structure and function of the double-strand break repair machinery. DNA Repair. 2004 Aug;3(8–9):863–873.
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002 Jan 25;108(2):171–182. doi: 10.1016/S0092-8674(02)00615-3
   PubMed Web of Science ®Google Scholar
• Chen CC, Feng W, Lim PX, et al. Homology-Directed Repair and the Role of BRCA1, BRCA2, and related proteins in genome integrity and cancer. Annu Rev Cancer Biol. 2018 Mar;2(1):313–336.
   PubMedGoogle Scholar
• Prakash R, Zhang Y, Feng W, et al. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015 Apr 1;7(4):a016600. doi: 10.1101/cshperspect.a016600
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21-28;378(6559):789–792. doi: 10.1038/378789a0
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Domchek SM, Nathanson KL, et al. Population frequency of germline BRCA1/2 mutations. J Clin Oncol. 2016;34(34):4183–4185. doi: 10.1200/JCO.2016.67.0554
   PubMed Web of Science ®Google Scholar
• Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996 Oct;14(2):185–187.
   PubMed Web of Science ®Google Scholar
• Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003 Feb 5;95(3):214–221. doi: 10.1093/jnci/95.3.214
   PubMedGoogle Scholar
• Hu C, Hart SN, Polley EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018 Jun 19;319(23):2401–2409. doi: 10.1001/jama.2018.6228
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 1;434(7035):917–921. doi: 10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Nat Acad Sci. 2011;108(8):3406–3411. doi: 10.1073/pnas.1013715108
   PubMed Web of Science ®Google Scholar
• Haber JE. DNA recombination: the replication connection. Trends Biochem Sci. 1999 Jul;24(7):271–275. doi: 10.1016/S0968-0004(99)01413-9
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break repair. J Clin Oncol. 2008;26(22):3785–3790. doi: 10.1200/JCO.2008.16.0812
   PubMed Web of Science ®Google Scholar
• Burki TK. AZD1775 plus chemoradiotherapy for pancreatic cancer. Lancet Oncol. 2019 Sep;20(9):e472. doi: 10.1016/S1470-2045(19)30537-6
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, De Oliveira E, Ottenhof N, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011 May 1;17(9):2799–2806. doi: 10.1158/1078-0432.CCR-10-2580
   PubMed Web of Science ®Google Scholar
• Cuneo KC, Morgan MA, Sahai V, et al. Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol. 2019 Oct 10;37(29):2643–2650. doi: 10.1200/JCO.19.00730
   PubMed Web of Science ®Google Scholar
• Gupta N, Huang T-T, Horibata S, et al. Cell cycle checkpoints and beyond: exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer. Pharmacol Res. 2022 Apr 1;178:106162. doi: 10.1016/j.phrs.2022.106162
   PubMed Web of Science ®Google Scholar
• Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov7;10(1):5065. doi: 10.1038/s41467-019-12836-9
   PubMed Web of Science ®Google Scholar
• Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003 Jul 15;66(2):225–237. doi: 10.1016/S0006-2952(03)00260-0
   PubMed Web of Science ®Google Scholar
• Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011 Jan;18(1):18–25. doi: 10.3747/co.v18i1.708
   PubMed Web of Science ®Google Scholar
• Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111(6):1132–1138. doi: 10.1038/bjc.2014.418
   PubMed Web of Science ®Google Scholar
• Reiss KA, Yu S, Judy R, et al. Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precision Oncol. 2018;2(2):1–9. doi: 10.1200/PO.17.00152
   PubMedGoogle Scholar
• Reiss KA, Mick R, O’Hara MH, et al. Phase II study of maintenance rucaparib in patients with Platinum-Sensitive Advanced pancreatic cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22):2497–2505. doi: 10.1200/JCO.21.00003
   PubMed Web of Science ®Google Scholar
• Reiss K, Hong S, Kasi A, et al. Apollo: a randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192. JCO. 2023 Jun 1;41(16_suppl):TPS4202. doi: 10.1200/JCO.2023.41.16_suppl.TPS4202
   Web of Science ®Google Scholar
• Higuchi T, Flies DB, Marjon NA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257–1268. doi: 10.1158/2326-6066.CIR-15-0044
   PubMed Web of Science ®Google Scholar
• Balli D, Rech AJ, Stanger BZ, et al. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin Cancer Res. 2017 Jun 15;23(12):3129–3138. doi: 10.1158/1078-0432.CCR-16-2128
   PubMed Web of Science ®Google Scholar
• Park W, O’Connor C, Chou JF, et al. Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy. J Clin Oncol. 2023;41(16_suppl):4140–4140. doi: 10.1200/JCO.2023.41.16_suppl.4140
   Web of Science ®Google Scholar
• Wittinghofer A, Pai EF. The structure of Ras protein: a model for a universal molecular switch. Trends Biochem Sci. 1991 Oct;16(10):382–387. doi: 10.1016/0968-0004(91)90156-P
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003 Jan;3(1):11–22. doi: 10.1038/nrc969
   PubMed Web of Science ®Google Scholar
• Bryant KL, Mancias JD, Kimmelman AC, et al. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39(2):91–100. doi: 10.1016/j.tibs.2013.12.004
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405. doi: 10.1038/nature11547
   PubMed Web of Science ®Google Scholar
• Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153–168. doi: 10.1038/s41575-019-0245-4
   PubMed Web of Science ®Google Scholar
• Kim MK, Woo SM, Park B, et al. Prognostic implications of multiplex detection of KRAS mutations in Cell-Free DNA from patients with pancreatic ductal adenocarcinoma. Clin Chem. 2018 Apr;64(4):726–734.
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28;503(7477):548–551. doi: 10.1038/nature12796
   PubMed Web of Science ®Google Scholar
• McCormick F. Targeting KRAS directly. Annual Rev Cancer Biol. 2018;2(1):81–90. doi: 10.1146/annurev-cancerbio-050216-122010
   Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020 Sep 24;383(13):1207–1217. doi: 10.1056/NEJMoa1917239
   PubMed Web of Science ®Google Scholar
• Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer. N Engl J Med. 2022;388(1):33–43. doi: 10.1056/NEJMoa2208470
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 2023;41(25):4097–4106. doi: 10.1200/JCO.23.00434
   PubMed Web of Science ®Google Scholar
• Bannoura SF, Khan HY, Azmi AS. KRAS G12D targeted therapies for pancreatic cancer: has the fortress been conquered? Front Oncol. 2022;12:1013902. doi: 10.3389/fonc.2022.1013902
   PubMed Web of Science ®Google Scholar
• Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022 Feb 24;65(4):3123–3133. doi: 10.1021/acs.jmedchem.1c01688
   PubMed Web of Science ®Google Scholar
• Mahadevan KK, McAndrews KM, LeBleu VS, et al. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell. 2023 Sep 11;41(9):1606–1620.e8. doi: 10.1016/j.ccell.2023.07.002
   PubMed Web of Science ®Google Scholar
• Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022 Oct;28(10):2171–2182.
   PubMed Web of Science ®Google Scholar
• Knox JE, Jiang J, Burnett GL, et al. Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models. Cancer Res. 2022;82(12_Supplement):3596–3596. doi: 10.1158/1538-7445.AM2022-3596
   Web of Science ®Google Scholar
• Mao Z, Xiao H, Shen P, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022 Jan 25;8(1):5. doi: 10.1038/s41421-021-00368-w
   PubMed Web of Science ®Google Scholar
• Punekar SR, Velcheti V, Neel BG, et al. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022 Oct 1;19(10):637–655. doi: 10.1038/s41571-022-00671-9
   PubMed Web of Science ®Google Scholar
• Arbour KC, Punekar S, Garrido-Laguna I, et al. 652O preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34:S458. doi: 10.1016/j.annonc.2023.09.1838
   Web of Science ®Google Scholar
• Lito P, Solomon M, Li LS, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016 Feb 5;351(6273):604–608. doi: 10.1126/science.aad6204
   PubMed Web of Science ®Google Scholar
• Nichols RJ, Haderk F, Stahlhut C, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Sep;20(9):1064–1073.
   PubMed Web of Science ®Google Scholar
• Hofmann MH, Gmachl M, Ramharter J, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-Driven cancers through combined MEK inhibition. Cancer Discov. 2021 Jan;11(1):142–157.
   PubMed Web of Science ®Google Scholar
• Srivastava N, Srivastava PK, Rich B. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS One. 2009 Jul 10;4(7):e6094. doi: 10.1371/journal.pone.0006094
   PubMed Web of Science ®Google Scholar
• Yuan TL, Fellmann C, Lee CS, et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014 Oct;4(10):1182–1197.
   PubMed Web of Science ®Google Scholar
• Ross SJ, Revenko AS, Hanson LL. et al. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med. 2017 Jun 14;9(394). doi: 10.1126/scitranslmed.aal5253
   Web of Science ®Google Scholar
• Tian Z, Liang G, Cui K, et al. Insight into the prospects for RNAi therapy of cancer. Front Pharmacol. 2021;12:644718. doi: 10.3389/fphar.2021.644718
   PubMedGoogle Scholar
• Golan T, Khvalevsky EZ, Hubert A, et al. Rnai therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015 Sep 15;6(27):24560–24570. doi: 10.18632/oncotarget.4183
   PubMedGoogle Scholar
• Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6(1):6744. doi: 10.1038/ncomms7744
   PubMedGoogle Scholar
• Raphael BJ, Aguirre A, Hruban R, et al. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185–203.e13.
   PubMed Web of Science ®Google Scholar
• Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022 Jun 13;28(12):2704–2714. doi: 10.1158/1078-0432.CCR-21-3581
   PubMed Web of Science ®Google Scholar
• Singhi AD, George B, Greenbowe JR, et al. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas identifies genetic alterations that might Be Targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156(8):2242–2253.e4. doi: 10.1053/j.gastro.2019.02.037
   PubMed Web of Science ®Google Scholar
• Guan M, Bender R, Pishvaian M, et al. Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs). JCO. 2018 Feb1;36(4_suppl):214. doi: 10.1200/JCO.2018.36.4_suppl.214
   Google Scholar
• Qian ZR, Rubinson DA, Nowak JA, et al. Association of alterations in main Driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4(3):e173420. doi: 10.1001/jamaoncol.2017.3420
   PubMed Web of Science ®Google Scholar
• McIntyre CA, Lawrence SA, Richards AL, et al. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. 2020;126(17):3939–3949. doi: 10.1002/cncr.33038
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer Institute of Canada Clinical Trials group. J Clin Oncol. 2007;25(15):1960–1966. doi: 10.1200/JCO.2006.07.9525
   PubMed Web of Science ®Google Scholar
• Qin S, Li J, Bai Y, et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2023;(0):JCO.22.02630.
   Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007 May 1;26(22):3291–3310. doi: 10.1038/sj.onc.1210422
   PubMed Web of Science ®Google Scholar
• Ciner AT, Jiang Y, Hausner P. BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities. Mol Cancer Res. 2023 Apr 1;21(4):293–300. doi: 10.1158/1541-7786.MCR-22-0626
   PubMed Web of Science ®Google Scholar
• Busch E, Kreutzfeldt S, Agaimy A, et al. Successful BRAF/MEK inhibition in a patient with BRAF V600E -mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud. 2020 Aug;6(4):a005553.
   PubMed Web of Science ®Google Scholar
• Li HS, Yang K, Wang Y. Remarkable response of BRAF (V600E)-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report. Gastroenterol Rep. 2022;10:goab031. doi: 10.1093/gastro/goab031
   Google Scholar
• Sasankan S, Rebuck L, Darrah G, et al. Metastatic pancreatic cancer with BRAF and P53 mutations: case report of therapeutic response to doublet targeted therapy. Case Rep Oncol. 2020 Sep;13(3):1239–1243.
   PubMed Web of Science ®Google Scholar
• Hendifar A, Blais EM, Wolpin B, et al. Retrospective case series analysis of RAF family alterations in pancreatic cancer: Real-World Outcomes from targeted and standard therapies. JCO Precision Oncol. 2021;5(5):1325–1338. doi: 10.1200/PO.20.00494
   Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nature Med. 2023 May 1;29(5):1103–1112. doi: 10.1038/s41591-023-02321-8
   PubMed Web of Science ®Google Scholar
• Gouda MA, Subbiah V. Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors. Am Soc Clin Oncol Educ Book. 2023;43(43):e404770. doi: 10.1200/EDBK_404770
   PubMedGoogle Scholar
• Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017 Apr 15;23(8):1988–1997. doi: 10.1158/1078-0432.CCR-16-1679
   PubMed Web of Science ®Google Scholar
• Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261–1273.
   PubMed Web of Science ®Google Scholar
• Duke ES, Bradford D, Marcovitz M, et al. FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res. 2023 Jun 2;Of1–of6. doi: 10.1158/1078-0432.CCR-23-2268
   PubMed Web of Science ®Google Scholar
• Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug;28(8):1640–1645.
   PubMed Web of Science ®Google Scholar
• Heining C, Horak P, Uhrig S, et al. NRG1 Fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 2018 Sep;8(9):1087–1095.
   PubMed Web of Science ®Google Scholar
• Schram A, Macarulla T, Cleary J, et al. 1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC). Ann Oncol. 2023;34:S895–S896. doi: 10.1016/j.annonc.2023.09.2567
   Web of Science ®Google Scholar
• Carrizosa DR, Burkard ME, Elamin YY, et al. CRESTONE: initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. J Clin Oncol. 2022;40(16_suppl):3006. doi: 10.1200/JCO.2022.40.16_suppl.3006
   PubMed Web of Science ®Google Scholar
• Kaplan DR, Hempstead BL, Martin-Zanca D, et al. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science. 1991 Apr 26;252(5005):554–558. doi: 10.1126/science.1850549
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Garrido-Laguna I, Liu SV, et al. Entrectinib in TRK and ROS1 fusion-positive metastatic pancreatic cancer. JCO Precis Oncol. 2018 Nov;2(2):1–7.
   PubMedGoogle Scholar
• Okamura R, Boichard A, Kato S, et al. Analysis of NTRK Alterations in Pan-cancer Adult and pediatric malignancies: implications for NTRK-Targeted therapeutics. JCO Precision Oncol. 2018;2(2):1–20. doi: 10.1200/PO.18.00183
   Google Scholar
• Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38–46. doi: 10.1038/s41379-019-0324-7
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731–739. doi: 10.1056/NEJMoa1714448
   PubMed Web of Science ®Google Scholar
• Krzakowski MJ, Lu S, Cousin S, et al. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. J Clin Oncol. 2022;40(16_suppl):3099. doi: 10.1200/JCO.2022.40.16_suppl.3099
   PubMedGoogle Scholar
• Fan N, Zhang Y, Zou S. Methylthioadenosine phosphorylase deficiency in tumors: a compelling therapeutic target. Front Cell Dev Biol. 2023;11:1173356. doi: 10.3389/fcell.2023.1173356
   PubMed Web of Science ®Google Scholar
• Zhu F, Rui L. PRMT5 in gene regulation and hematologic malignancies. Genes Dis. 2019 Sep;6(3):247–257. doi: 10.1016/j.gendis.2019.06.002
   PubMed Web of Science ®Google Scholar
• Marjon K, Cameron MJ, Quang P, et al. MTAP Deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 Axis. Cell Rep. 2016 Apr 19;15(3):574–587. doi: 10.1016/j.celrep.2016.03.043
   PubMed Web of Science ®Google Scholar
• Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26580–26590. doi: 10.1073/pnas.1911273116
   PubMed Web of Science ®Google Scholar
• Rodon J, Doi T, Noboru Y, et al. Editor poster (LB_B14): initial results from first-in-human study of AMG 193, an MTA-Cooperative PRMT5 inhibitor, in Biomarker-Selected Solid Tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2023 2023 Oct 13; Boston, MA, USA.
   Google Scholar
• Tanaka M, Shibahara J, Fukushima N, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011 Oct;59(10):942–952.
   PubMed Web of Science ®Google Scholar
• Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008 Dec 1;14(23):7624–7634. doi: 10.1158/1078-0432.CCR-08-1547
   PubMed Web of Science ®Google Scholar
• Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999 Feb;9(1):89–96. doi: 10.1016/S0959-437X(99)80013-6
   PubMed Web of Science ®Google Scholar
• Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem. 2005;74(1):681–710. doi: 10.1146/annurev.biochem.74.082803.133243
   PubMedGoogle Scholar
• Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem. 1996;65(1):101–133. doi: 10.1146/annurev.bi.65.070196.000533
   PubMedGoogle Scholar
• Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019 Nov 1;121(10):809–818. doi: 10.1038/s41416-019-0599-y
   PubMed Web of Science ®Google Scholar
• Buchler T. Microsatellite instability and metastatic colorectal cancer - a clinical perspective. Front Oncol. 2022;12:888181. doi: 10.3389/fonc.2022.888181
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019 Oct 1;5(10):1431–1438. doi: 10.1001/jamaoncol.2019.1588
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct;33(8):828–833.
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. [cited 2023 Oct 2]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors
   Google Scholar
• Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–150. doi: 10.1038/s41586-023-06063-y
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccin. 2019 Feb 8;4(1):7. doi: 10.1038/s41541-019-0103-y
   PubMed Web of Science ®Google Scholar
• DD MR, Hartley ML, Noel MS. The role of immunotherapy in pancreatic cancer. Curr Oncol. 2022 Sep 23;29(10):6864–6892. doi: 10.3390/curroncol29100541
   PubMed Web of Science ®Google Scholar
• Ding Z, Li Q, Zhang R, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Ther. 2021 Jan 20;6(1):26. doi: 10.1038/s41392-020-00448-5
   PubMed Web of Science ®Google Scholar
• Beatty GL, O’Hara MH, Lacey SF, et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a phase 1 trial. Gastroenterology. 2018 Jul;155(1):29–32.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen M, Wu Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7(7):e1440169. doi: 10.1080/2162402X.2018.1440169
   PubMed Web of Science ®Google Scholar
• Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-Cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112–2119. doi: 10.1056/NEJMoa2119662
   PubMed Web of Science ®Google Scholar
• Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18(1):123–148. doi: 10.1146/annurev-pathmechdis-031621-024600
   PubMedGoogle Scholar
• Grünwald BT, Devisme A, Andrieux G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021 Oct 28;184(22):5577–5592.e18. doi: 10.1016/j.cell.2021.09.022
   PubMed Web of Science ®Google Scholar
• Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021 Sep 7;326(9):851–862. doi: 10.1001/jama.2021.13027
   PubMed Web of Science ®Google Scholar
• Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007 Oct 1;67(19):9518–9527. doi: 10.1158/0008-5472.CAN-07-0175
   PubMed Web of Science ®Google Scholar
• Zhang Y, Velez-Delgado A, Mathew E, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017 Jan;66(1):124–136.
   PubMed Web of Science ®Google Scholar
• Hegde S, Krisnawan VE, Herzog BH, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020 Mar 16;37(3):289–307.e9. doi: 10.1016/j.ccell.2020.02.008
   PubMed Web of Science ®Google Scholar
• Lin JH, Huffman AP, Wattenberg MM. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J Exp Med. 2020 Aug 3;217(8). doi: 10.1084/jem.20190673
   Web of Science ®Google Scholar
• Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013 Feb 1;73(3):1128–1141. doi: 10.1158/0008-5472.CAN-12-2731
   PubMed Web of Science ®Google Scholar
• Janson C, Jung H, Ertl L, et al. Abstract 5655: Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer. Cancer Res. 2017;77(13_Supplement):5655. doi: 10.1158/1538-7445.AM2017-5655
   Google Scholar
• Linehan D, Noel MS, Hezel AF, et al. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: correlation with blood monocyte counts. Am Soc Clin Oncol. 2018;36(5_suppl):92. doi: 10.1200/JCO.2018.36.5_suppl.92
   Web of Science ®Google Scholar
• Wang-Gillam A, Nywening TM, Sanford DE, et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC). American Society of Clinical Oncology. 2015.
   Google Scholar
• Noel M, O’Reilly EM, Wolpin BM, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020 Jun;38(3):800–811.
   PubMed Web of Science ®Google Scholar
• Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016 May;17(5):651–662.
   PubMed Web of Science ®Google Scholar
• Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. 2009 Oct;21(5):265–272. doi: 10.1016/j.smim.2009.05.010
   PubMed Web of Science ®Google Scholar
• O’Hara MH, O’Reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 Jan;22(1):118–131.
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846–859. doi: 10.1016/j.ccr.2014.05.016
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014 Sep 15;74(18):5057–5069. doi: 10.1158/0008-5472.CAN-13-3723
   PubMed Web of Science ®Google Scholar